Repligen (NASDAQ:RGEN) Price Target Lowered to $190.00 at JPMorgan Chase & Co.

Repligen (NASDAQ:RGEN) had its price target decreased by JPMorgan Chase & Co. from $200.00 to $190.00 in a research report released on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

Several other analysts have also recently weighed in on the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Monday. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a report on Tuesday. Finally, Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Stock Performance

RGEN opened at $139.43 on Tuesday. The stock has a market cap of $7.83 billion, a price-to-earnings ratio of -273.39, a PEG ratio of 4.54 and a beta of 1.27. The business has a 50 day moving average of $139.19 and a 200-day moving average of $145.93. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $102.97 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 earnings per share. On average, equities research analysts expect that Repligen will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RGEN. Tidal Investments LLC raised its holdings in Repligen by 142.8% in the 3rd quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 6,558 shares during the last quarter. Peapack Gladstone Financial Corp bought a new position in Repligen in the 3rd quarter valued at approximately $296,000. Franklin Resources Inc. raised its holdings in Repligen by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company’s stock worth $47,551,000 after purchasing an additional 26,668 shares during the last quarter. GAMMA Investing LLC raised its holdings in Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares during the last quarter. Finally, Everence Capital Management Inc. bought a new position in Repligen during the 4th quarter worth approximately $294,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.